Differing levels of testosterone and the prostate: A physiological interplay

Nature Reviews Urology

Volumn 8, Issue 7, 2011, Pages 365-377

  Goldenberg, S Larry ^a   Koupparis, Anthony ^a   Robinson, Michael E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANEDIOL; ANDROSTANOLONE; ANDROSTENEDIONE; BASIC FIBROBLAST GROWTH FACTOR; CYTOCHROME P450 3A5; DNA POLYMERASE; ESTRADIOL; PRASTERONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; TESTOSTERONE PROPIONATE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ANDROGEN DEFICIENCY; ANGIOGENESIS; APOPTOSIS; AUTOPHAGY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CARCINOGENESIS; CASTRATION; CELL DIFFERENTIATION; CELL DIVISION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); DNA POLYMORPHISM; DNA SYNTHESIS; DOSE RESPONSE; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; GENETIC CODE; GENETIC ENGINEERING; HEREDITY; HOMEOSTASIS; HORMONE SUBSTITUTION; HUMAN; MEDLINE; METASTASIS; MITOSIS RATE; NONHUMAN; ORGAN GROWTH; PHENOTYPE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RECEPTOR BINDING; REVIEW; RISK REDUCTION; SECRETION; STEROIDOGENESIS; TESTOSTERONE REPLACEMENT THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; X CHROMOSOME;

ANIMALS; DIHYDROTESTOSTERONE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; PROSTATE; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 79960241138     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.79     Document Type: Review

References (123)

1. Wang, C. et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Int. J. Impot. Res. 21, 1-8 (2009).
2. Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J. & Blackman, M. R. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J. Clin. Endocrinol. Metab. 86, 724-731 (2001). (Pubitemid 32207487)
3. Araujo, A. B. et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab. 89, 5920-5926 (2004). (Pubitemid 39628393)
4. Wu, F. C. et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J. Clin. Endocrinol. Metab. 93, 2737-2745 (2008). (Pubitemid 352008544)
5. Gooren, L. J., Behre, H. M., Saad, F., Frank, A. & Schwerdt, S. Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research. Aging Male 10, 173-181 (2007). (Pubitemid 350146724)
6. Huggins, C. & Hodges, C. V. Studies on prostatic cancer I: the effect of castration, of estrogen and of androgen injection on serum phospatases in metastatic carcinoma of the prostate. Cancer Res. 19, 293-297 (1941).
7. Huggins, C., Stevens, R. E. & Hodges, C. V. Studies on prostatic cancer II: the effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43, 209-223 (1941).
8. Bhasin, S. et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 95, 2536-2559 (2010).
9. Chute, R. & Willetts, A. T. The treatment of cancer of the prosate with castration and the administration of estrogen. N. Engl. J. Med. 227, 863-869 (1942).
10. Moore, C. R., Hughes, W. & Gallagher, T. F. Rat seminal-vesicle cytology as a testis-hormone indicator and the prevention of castration changes by the testis-extract injection. Am. J. Anat. 45, 109-131 (1930).
11. Moore, C. R., Price, D. & Gallagher, T. F. Rat-prostate cytology as a testis-hormone indicator and the prevention of castration changes by testis-extract injections. Am. J. Anat. 45, 71-107 (1930).
12. Burkhart, E. Z. A study of the early effects of androgenic substances in the rat by the aid of colchicine. J. Exp. Zool. 89, 135-165 (1942).
13. Huggins, C. Endocrine-induced regression of cancers. Cancer Res. 27, 1925-1930 (1967).
14. Sheppard, H., Tsien, W. H., Mayer, P. & Howie, N. Metabolism of the accessory sex organs of the immature male rat: changes in nucleic acid composition and uptake of thymidine-3H induced by castration and methandrostenolone. Biochem. Pharmacol. 14, 41-51 (1965).
15. Coffey, D. S., Shimazaki, J. & Williams-Ashman, H. G. Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growth. Arch. Biochem. Biophys. 124, 184-198 (1968).
16. Lesser, B. & Bruchovsky, N. The effects of testosterone, 5-dihydrotestosterone and adenosine 3', 5'-monophosphate on cell proliferation and differentiation in rat prostate. Biochim. Biophys. Acta 308, 426-437 (1973).
17. Lesser, B. & Bruchovsky, N. Effect of duration of the period after castration on the response of the rat ventral prostate to androgens. Biochem. J. 142, 429-431 (1974).
18. Bruchovsky, N., Lesser, B., Van Doorn, E. & Craven, S. Hormonal effects on cell proliferation in rat prostate. Vitam. Horm. 33, 61-102 (1975).
19. Wright, A. S., Douglas, R. C., Thomas, L. N., Lazier, C. B. & Rittmaster, R. S. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5?-reductase. Endocrinology 140, 4509-4515 (1999). (Pubitemid 30666115)
20. Rittmaster, R. S., Magor, K. E., Manning, A. P., Norman, R. W. & Lazier, C. B. Differential effect of 5?-reductase inhibition and castration on androgen-regulated gene expression in rat prostate. Mol. Endocrinol. 5, 1023-1029 (1991).
21. Fowler, J. E. Jr & Whitmore, W. F. Jr The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J. Urol. 126, 372-375 (1981). (Pubitemid 11061000)
22. Morgentaler, A. & Traish, A. M. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur. Urol. 55, 310-320 (2009).
23. Morgentaler, A., Lipshultz, L. I., Bennett, R., Sweeney, M., Avila, D. & Khera, M. Testosterone therapy in men with untreated prostate cancer. J. Urol. 195, 1256-1261 (2011).
24. Khera, M. Androgen replacement therapy after cancer treatment. Curr. Urol. Rep. 11, 393-399 (2010).
25. Bosland, M. C. The role of steroid hormones in prostate carcinogenesis. J. Natl Cancer Inst. Monogr. 39-66 (2000).
26. Morgentaler, A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur. Urol. 50, 935-939 (2006). (Pubitemid 44486489)
27. Banach-Petrosky, W. et al. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Res. 67, 9089-9096 (2007). (Pubitemid 47535894)
28. Roddam, A. W., Allen, N. E., Appleby, P. & Key, T. J. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J. Natl Cancer Inst. 100, 170-183 (2008). (Pubitemid 351480553)
29. Stattin, P. et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int. J. Cancer 108, 418-424 (2004). (Pubitemid 37549608)
30. Raynaud, J. P. Prostate cancer risk in testosterone-treated men. J. Steroid Biochem. Mol. Biol. 102, 261-266 (2006).
31. Sher, D. J. et al. Absence of relationship between steroid hormone levels and prostate cancer tumor grade. Urology 73, 356-361; discussion 361-352 (2009).
32. Severi, G. et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 15, 86-91 (2006).
33. Salonia, A. et al. Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. Cancer doi:10.1002/cncr.25985 (2011).
34. Imamoto, T. et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur. Urol. 47, 308-312 (2005). (Pubitemid 40248848)
35. Isom-Batz, G. et al. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J. Urol. 173, 1935-1937 (2005). (Pubitemid 40675215)
36. Massengill, J. C. et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J. Urol. 169, 1670-1675 (2003). (Pubitemid 36443468)
37. Morgentaler, A. Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship. Eur. Urol. 52, 623-625 (2007). (Pubitemid 47126171)
38. Imamoto, T. et al. Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients? Prostate Cancer Prostatic Dis. 12, 78-82 (2009).
39. Hsing, A. W. Hormones and prostate cancer: whats next? Epidemiol. Rev. 23, 42-58 (2001). (Pubitemid 32906613)
40. Gann, P. H., Hennekens, C. H., Ma, J., Longcope, C. & Stampfer, M. J. Prospective study of sex hormone levels and risk of prostate cancer. J. Natl Cancer Inst. 88, 1118-1126 (1996). (Pubitemid 26274606)
41. Rhoden, E. L. & Morgentaler, A. Risks of testosterone-replacement therapy and recommendations for monitoring. N. Engl. J. Med. 350, 482-492 (2004). (Pubitemid 38133769)
42. Pierorazio, P. M. et al. Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int. 105, 824-829 (2010).
43. Heracek, J. et al. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Steroids 72, 375-380 (2007). (Pubitemid 46452717)
44. Marks, L. S. et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 296, 2351-2361 (2006). (Pubitemid 44749363)
45. Edwards, A., Hammond, H. A., Jin, L., Caskey, C. T. & Chakraborty, R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 12, 241-253 (1992).
46. Chang, C. S., Kokontis, J. & Liao, S. T. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240, 324-326 (1988).
47. Chamberlain, N. L., Driver, E. D. & Miesfeld, R. L. The length and location of CAG trinucleotide repeats in the androgen receptor N.-terminal domain affect transactivation function. Nucleic Acids Res. 22, 3181-3186 (1994). (Pubitemid 24260654)
48. Giovannucci, E. et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl Acad. Sci. USA 94, 3320-3323 (1997). (Pubitemid 27157309)
49. Stanford, J. L. et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res. 57, 1194-1198 (1997). (Pubitemid 27138622)
50. Moilanen, A. M. et al. Characterization of androgen-regulated expression of CYP3A5 in human prostate. Carcinogenesis 28, 916-921 (2007).
51. Gao, J., Arnold, J. T. & Isaacs, J. T. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res. 61, 5038-5044 (2001). (Pubitemid 32681532)
52. Chan, J. M. et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279, 563-566 (1998). (Pubitemid 28067285)
53. Damon, S. E., Maddison, L., Ware, J. L. & Plymate, S. R. Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation. Endocrinology 139, 3456-3464 (1998). (Pubitemid 28512302)
54. Munzer, T. et al. Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men. Am. J. Physiol. Endocrinol. Metab. 290, E1006-E1013 (2006).
55. Peng, L., Malloy, P. J., Wang, J. & Feldman, D. Growth inhibitory concentrations of androgens up-regulate insulin-like growth factor binding protein-3 expression via an androgen response element in LNCaP human prostate cancer cells. Endocrinology 147, 4599-4607 (2006). (Pubitemid 44402165)
56. Cohen, P. et al. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J. Clin. Endocrinol. Metab. 75, 1046-1053 (1992).
57. Risbridger, G. P., Bianco, J. J., Ellem, S. J. & McPherson, S. J. Oestrogens and prostate cancer. Endocr. Relat. Cancer 10, 187-191 (2003). (Pubitemid 36758648)
58. Giovannucci, E., Rimm, E. B., Stampfer, M. J., Colditz, G. A. & Willett, W. C. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 9, 3-9 (1998). (Pubitemid 28048654)
59. Weiderpass, E., Ye, W., Vainio, H., Kaaks, R. & Adami, H. O. Reduced risk of prostate cancer among patients with diabetes mellitus. Int. J. Cancer 102, 258-261 (2002). (Pubitemid 35222294)
60. Stattin, P. et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J. Clin. Endocrinol. Metab. 86, 1341-1345 (2001). (Pubitemid 32323026)
61. Bubley, G. J. Is the flare phenomenon clinically significant? Urology 58, 5-9 (2001). (Pubitemid 32743396)
62. Freedland, S. J. & Partin, A. W. Prostate-specific antigen: update. Urology 67, 458-460 (2006) (2006).
63. Tomera, K. et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J. Urol. 165, 1585-1589 (2001). (Pubitemid 32410246)
64. Kuhn, J. M. et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N. Engl. J. Med. 321, 413-418 (1989).
65. Bruchovsky, N., Klotz, L., Crook, J. & Goldenberg, S. L. Locally advanced prostate cancer-biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer 109, 858-867 (2007). (Pubitemid 46333527)
66. Buchan, N. C. & Goldenberg, S. L. Intermittent androgen suppression for prostate cancer. Nat. Rev. Urol. 7, 552-560 (2010).
67. Bhasin, S. et al. Testosterone dose-response relationships in healthy young men. Am. J. Physiol. Endocrinol. Metab. 281, E1172-E1181 (2001).
68. Cooper, C. S. et al. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J. Urol. 159, 441-443 (1998). (Pubitemid 28049252)
69. Gould, D. C., Feneley, M. R. & Kirby, R. S. Prostate-specific antigen testing in hypogonadism: implications for the safety of testosterone- replacement therapy. BJU Int. 98, 1-4 (2006). (Pubitemid 43885494)
70. Behre, H. M., Bohmeyer, J. & Nieschlag, E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin. Endocrinol. (Oxf.) 40, 341-349 (1994). (Pubitemid 24194627)
71. Swerdloff, R. S. & Wang, C. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male 6, 207-211 (2003). (Pubitemid 37411891)
72. Roberts, J. T. & Essenhigh, D. M. Adenocarcinoma of prostate in 40-year-old body-builder. Lancet 328, 742 (1986). (Pubitemid 16022226)
73. Guinan, P. D. et al. Impotence therapy and cancer of the prostate. Am. J. Surg. 131, 599-600 (1976).
74. Jackson, J. A., Waxman, J. & Spiekerman, A. M. Prostatic complications of testosterone replacement therapy. Arch. Intern. Med. 149, 2365-2366 (1989). (Pubitemid 19258185)
75. Loughlin, K. R. & Richie, J. P. Prostate cancer after exogenous testosterone treatment for impotence. J. Urol. 157, 1845 (1997). (Pubitemid 27171790)
76. Curran, M. J. & Bihrle, W. 3rd. Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 53, 423-424 (1999). (Pubitemid 29063343)
77. Gaylis, F. D. et al. Prostate cancer in men using testosterone supplementation. J. Urol. 174, 534-538; discussion 538 (2005). (Pubitemid 40981594)
78. Bassil, N., Alkaade, S. & Morley, J. E. The benefits and risks of testosterone replacement therapy: a review. Ther. Clin. Risk Manag. 5, 427-448 (2009).
79. Gould, D. C. & Kirby, R. S. Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer? Prostate Cancer Prostatic Dis. 9, 14-18 (2006). (Pubitemid 43378862)
80. Kirby, R. & Gould, D. Testosterone replacement therapy in hypogonadal men and prostate cancer risk. BJU Int. 96, 471-472 (2005). (Pubitemid 41224309)
81. Bhasin, S. et al. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J. Androl. 24, 299-311 (2003). (Pubitemid 39571784)
82. Barqawi, A. B. & Crawford, E. D. Testosterone replacement therapy and the risk of prostate cancer: a perspective view. Int. J. Impot. Res. 17, 462-463 (2005). (Pubitemid 43093249)
83. Barqawi, A. & Crawford, E. D. Testosterone replacement therapy and the risk of prostate cancer. Is there a link? Int. J. Impot. Res. 18, 323-328 (2006).
84. Stanworth, R. D. & Jones, T. H. Testosterone for the aging male; current evidence and recommended practice. Clin. Interv. Aging 3, 25-44 (2008). (Pubitemid 351559801)
85. Rhoden, E. L. & Averbeck, M. A. Testosterone therapy and prostate carcinoma. Curr. Urol. Rep. 10, 453-459 (2009).
86. Hajjar, R. R., Kaiser, F. E. & Morley, J. E. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J. Clin. Endocrinol. Metab. 82, 3793-3796 (1997). (Pubitemid 27509374)
87. Shabsigh, R., Crawford, E. D., Nehra, A. & Slawin, K. M. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int. J. Impot. Res. 21, 9-23 (2009).
88. Tenover, J. S. Effects of testosterone supplementation in the aging male. J. Clin. Endocrinol. Metab. 75, 1092-1098 (1992).
89. Dobs, A. S. et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J. Clin. Endocrinol. Metab. 84, 3469-3478 (1999). (Pubitemid 30645193)
90. Wang, C. et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. 89, 2085-2098 (2004). (Pubitemid 38619836)
91. Wang, C. et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J. Clin. Endocrinol. Metab. 85, 2839-2853 (2000). (Pubitemid 32269162)
92. Sih, R. et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J. Clin. Endocrinol. Metab. 82, 1661-1667 (1997). (Pubitemid 127495166)
93. Guay, A. T., Perez, J. B., Fitaihi, W. A. & Vereb, M. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer. Endocr. Pract. 6, 132-138 (2000).
94. Svetec, D. A., Canby, E. D., Thompson, I. M. & Sabanegh, E. S. Jr. The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction. J. Urol. 158, 1775-1777 (1997). (Pubitemid 27433150)
95. Kenny, A. M., Prestwood, K. M., Gruman, C. A., Marcello, K. M. & Raisz, L. G. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J. Gerontol. A Biol. Sci. Med. Sci. 56, M266-M272 (2001). (Pubitemid 32381803)
96. Gooren, L. J. A ten-year safety study of the oral androgen testosterone undecanoate. J. Androl. 15, 212-215 (1994). (Pubitemid 24218140)
97. Gerstenbluth, R. E., Maniam, P. N., Corty, E. W. & Seftel, A. D. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J. Androl. 23, 922-926 (2002). (Pubitemid 36300984)
98. Snyder, P. J. et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J. Clin. Endocrinol. Metab. 84, 1966-1972 (1999). (Pubitemid 30647018)
99. Schubert, M. et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J. Clin. Endocrinol. Metab. 89, 5429-5434 (2004). (Pubitemid 39518421)
100. Feneley, M. R. & Carruthers, M. PSA monitoring during testosterone replacement therapy: low long-term risk of prostate cancer with improved opportunity for cure. Andrologia 36, 212 (2004).
101. Rhoden, E. L. & Morgentaler, A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J. Urol. 170, 2348-2351 (2003). (Pubitemid 37413994)
102. Snyder, P. J. et al. Effects of testosterone replacement in hypogonadal men. J. Clin. Endocrinol. Metab. 85, 2670-2677 (2000). (Pubitemid 32269134)
103. Calof, O. M. et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J. Gerontol. A Biol. Sci. Med. Sci. 60, 1451-1457 (2005). (Pubitemid 41798454)
104. Lefkowitz, G. K., Taneja, S. S., Brown, J., Melamed, J. & Lepor, H. Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J. Urol. 168, 1415-1418 (2002). (Pubitemid 35034136)
105. Haggman, M. J., Macoska, J. A., Wojno, K. J. & Oesterling, J. E. The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J. Urol. 158, 12-22 (1997). (Pubitemid 27251585)
106. Nesbit, R. M. & Baum, W. C. Endocrine control of prostatic carcinoma; clinical and statistical survey of 1, 818 cases. J. Am. Med. Assoc. 143, 1317-1320 (1950).
107. Brendler, H., Chase, W. E. & Scott, W. W. Prostatic cancer; further investigation of hormonal relationships. Arch. Surg. 61, 433-440 (1950).
108. Prout, G. R. Jr & Brewer, W. R. Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer 20, 1871-1878 (1967).
109. Pearson, O. H. Discussion of Dr. Huggins paper: Control of cancers of man by endocrinological methods. Cancer Res. 17, 473-479 (1957).
110. Rawson, R. W. Hormonal control of neoplastic growth. Bull. N. Y. Acad. Med. 29, 595-611 (1953).
111. Kaufman, J. M. & Graydon, R. J. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J. Urol. 172, 920-922 (2004). (Pubitemid 39096423)
112. Agarwal, P. K. & Oefelein, M. G. Testosterone replacement therapy after primary treatment for prostate cancer. J. Urol. 173, 533-536 (2005).
113. Sarosdy, M. F. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 109, 536-541 (2007). (Pubitemid 46190961)
114. Khera, M. et al. Testosterone replacement therapy following radical prostatectomy. J. Sex. Med. 6, 1165-1170 (2009).
115. Rhoden, E. L., Averbeck, M. A. & Teloken, P. E. Androgen replacement in men undergoing treatment for prostate cancer. J. Sex. Med. 5, 2202-2208 (2008).
116. Zitzmann, M., Faber, S. & Nieschlag, E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J. Clin. Endocrinol. Metab. 91, 4335-4343 (2006). (Pubitemid 44833407)
117. Wu, F. C. et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N. Engl. J. Med. 363, 123-135 (2010).
118. Stanworth, R. D., Kapoor, D., Channer, K. S. & Jones, T. H. Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. Eur. J. Endocrinol. 159, 739-746 (2008).
119. Shores, M. M., Matsumoto, A. M., Sloan, K. L. & Kivlahan, D. R. Low serum testosterone and mortality in male veterans. Arch. Intern. Med. 166, 1660-1665 (2006). (Pubitemid 44232378)
120. Laughlin, G. A., Barrett-Connor, E. & Bergstrom, J. Low serum testosterone and mortality in older men. J. Clin. Endocrinol. Metab. 93, 68-75 (2008).
121. [No listed authors] Medication Guides. FDA [online], http://www.fda.gov/ Drugs/DrugSafety/UCM085729 (2011).
122. Malkin, C. J. et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 96, 1821-1825 (2010).
123. Basaria, S. et al. Adverse events associated with testosterone administration. N. Engl. J. Med. 363, 109-122 (2010).